European Medicines Agency (EMA) Approves Aegerion's Lojuxta for HoFH
First-in-Class MTP Inhibitor Enters European Market
The European Medicines Agency (EMA) has granted final marketing authorization for Lojuxta (lomitapide), developed by Aegerion Pharmaceuticals, for the treatment of Homozygous Familial Hypercholesterolemia (HoFH). Lojuxta works by inhibiting Microsomal Triglyceride Transfer Protein (MTP), directly blocking the synthesis of Low-Density Lipoprotein (LDL) cholesterol in the liver. Unlike traditional statin therapies, which rely on LDL receptor activity, Lojuxta provides a novel alternative for patients with severe HoFH who have receptor defects, offering a potent lipid-lowering effect. This approval provides a new treatment pathway for rare disease patients in Europe who are at high risk of early cardiovascular disease due to genetic defects.
Efficacy and Safety Demonstrated in Phase 3 Clinical Data
The marketing authorization was based on robust efficacy data from a single-arm, open-label Phase 3 trial in adult HoFH patients. Clinical results showed that patients experienced an average 50% reduction in LDL cholesterol (LDL-C) from baseline within 26 weeks when Lojuxta was added to existing lipid-lowering therapies. However, due to the drug's mechanism of action, gastrointestinal adverse events such as diarrhea and vomiting, as well as hepatic fat accumulation and elevated transaminase levels, may occur, necessitating regular monitoring. EMA granted approval under the condition of a strict Risk Management Plan (RMP) to manage these side effects, which is expected to be a key criterion for future prescribing safety.
Rights Transfer to Multinational Pharma and Commercialization Journey
The rights to Lojuxta were transferred from its developer, Aegerion, following bankruptcy and restructuring to Amryt Pharma, and ultimately to Chiesi Group in 2023, when Chiesi acquired Amryt for $1.48 billion. As a high-cost orphan drug with annual treatment costs in the hundreds of thousands of dollars per patient, Lojuxta has served as a strong cash cow. In Europe, where reimbursement decisions by national health authorities significantly impact revenue growth, the EMA approval provides a critical legal foundation to initiate pricing negotiations. This enables Chiesi to expand its specialty pharmaceutical portfolio and realize commercial synergies across Europe.
Pediatric Indication Expansion and Market Outlook Amid Intensifying Competition
The global HoFH treatment market is estimated to range from $80 million to $580 million, with Lojuxta competing against strong latecomers such as Amgen's Repatha (evolocumab) and Regeneron's Evkeeza (evinacumab). Nevertheless, Lojuxta has continued to strengthen its market position by expanding its indication to include patients aged five years and older in Europe in June 2026. The expansion into the pediatric rare disease market is expected to significantly extend the drug's life cycle and maximize revenue stability by prolonging prescription duration. With long-term clinical safety data, Lojuxta continues to demonstrate differentiated clinical value despite competitive pressures.
The EMA approval of Lojuxta marks a critical milestone in securing a dominant position in the global HoFH rare disease treatment market, estimated to range from $80 million to $580 million. The 50% LDL-C reduction from baseline observed in Phase 3 trials serves as a strong clinical benchmark in the ongoing market share competition with formidable latecomers such as Amgen's Repatha and Regeneron's Evkeeza. In the short term, the approval accelerates negotiations with European health authorities for pricing and reimbursement, laying the groundwork for immediate commercial revenue generation. In the medium to long term, the expansion of the indication to include patients aged five years and older in 2026 will further extend the prescription period for this high-cost treatment, thereby ensuring long-term revenue stability. Ultimately, the $1.48 billion acquisition of Amryt Pharma by Chiesi validates the value of its rare disease-focused pipeline and drives a virtuous cycle of follow-on R&D investment.
Source: EMA (ema)